Research article · 24 Feb 2025
Conference abstractPublished 26 Jul 2017
Nutraceuticals as promising agents in the prevention and treatment of atherosclerosis
Cardiff University, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Atherosclerosis, an inflammatory disorder of medium and large arteries and the underlying cause of myocardial infarction and cerebrovascular accident, is responsible for more deaths worldwide than any other disease. Pharmaceutical intervention together with lifestyle changes have recently resulted in a slight reduction in morbidity and mortality from atherosclerosis and its complications, at least in the western world. However, this is expected to change in the future, because of global increase in risk factors such as obesity and diabetes. Current pharmaceutical therapies against atherosclerosis such as statins are not fully effective and associated with several side effects together with patient-dependent efficacy. Unfortunately, many pharmaceutical leads against established targets have proved disappointing at the clinical level (e.g. inhibitors against cholesterol ester transfer protein). It is therefore essential that further research is carried out into alternative therapies for the prevention and/or treatment of atherosclerosis. Nutraceuticals have recently received substantial interest for the prevention/ treatment of atherosclerosis. However, more in-depth understanding is required on the molecular mechanisms underlying the actions of nutraceuticals together with large clinical trials testing their efficacy. We have recently initiated studies on the effects of many nutraceuticals, including certain omega-6-fatty acids, polyphenols and flavanols, on several key monocyte/ macrophage processes associated with atherosclerosis in vitro (e.g. monocytic migration, macrophage polarization, foam cell formation, activation of inflammasome and production of reactive oxygen species) and various risk factors in vivo. These will be presented in the context of current therapies and those that are being developed.
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical & Experimental Pathology.
Research article · 3 Feb 2025
Outbreak of Crimean Congo Haemorrhagic Fever in Northern Senegal in 2022
Review article · 16 Jan 2025
Recent Updates on Huntington Disease
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Pathology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Dipak P Ramji”
- BylineArticles whose byline prints “Thomas S Davies”
- BylineArticles whose byline prints “Hayley Gallagher”
- BylineArticles whose byline prints “Joe W E Moss”
- BylineArticles whose byline prints “Jessica Williams”
- BylineArticles whose byline prints “Wijdan Al-Ahmadi”
- BylineArticles whose byline prints “Victoria OâÂ?Â?Morain”